EUVIMEDEUVIMED entdecken
Crossref

The RNA-editing enzyme ADAR1: a regulatory hub that tunes multiple dsRNA-sensing pathways

Taisuke Nakahama, Yukio Kawahara iD

International Immunology · 14.03.2023 · 35 (3) · 123-133

DOI: 10.1093/intimm/dxac056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunology, online erschienen am 05.12.2022. Verfasst von Taisuke Nakahama und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of RNA Biology and Neuroscience, Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan. Hauptthemen laut MEDLINE: RNA Editing, RNA, Double-Stranded. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 96 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Ministry of Education, Culture, Sports, Science and Technology, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adenosine deaminase acting on RNA 1 (ADAR1) is an RNA-editing enzyme that catalyzes adenosine-to-inosine conversions in double-stranded RNAs (dsRNAs). In mammals, ADAR1 is composed of two isoforms: a nuclear short p110 isoform and a cytoplasmic long p150 isoform. Whereas both isoforms contain right-handed dsRNA-binding and deaminase domains, ADAR1 p150 harbors a Zα domain that binds to left-handed dsRNAs, termed Z-RNAs. Myeloma differentiation-associated gene 5 (MDA5) sensing of endogenous dsRNAs as non-self leads to the induction of type I interferon (IFN)-stimulated genes, but recent studies revealed that ADAR1 p150-mediated RNA editing, but not ADAR1 p110, prevents this MDA5-mediated sensing. ADAR1 p150-specific RNA-editing sites are present and at least a Zα domain–Z-RNA interaction is required for this specificity. Mutations in the ADAR1 gene cause Aicardi–Goutières syndrome (AGS), an infant encephalopathy with type I IFN overproduction. Insertion of a point mutation in the Zα domain of the Adar1 gene induces AGS-like encephalopathy in mice, which is rescued by concurrent deletion of MDA5. This finding indicates that impaired ADAR1 p150-mediated RNA-editing is a mechanism underlying AGS caused by an ADAR1 mutation. ADAR1 p150 also prevents ZBP1 sensing of endogenous Z-RNA, which leads to programmed cell death, via the Zα domain and its RNA-editing activity. Furthermore, ADAR1 prevents protein kinase R (PKR) sensing of endogenous right-handed dsRNAs, which leads to translational shutdown and growth arrest. Thus, ADAR1 acts as a regulatory hub that blocks sensing of endogenous dsRNAs as non-self by multiple sensor proteins, both in RNA editing-dependent and -independent manners, and is a potential therapeutic target for diseases, especially cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA EditingRNA, Double-StrandedMiceAnimalsAdenosine DeaminaseProtein IsoformsInterferon-Induced Helicase, IFIH1ApoptosisMammalsRNA-Binding Proteins

Stichwörter der Autor:innen

Aicardi–Goutières syndromeMDA5PKRZ-RNAZBP1

Substanzen

RNA, Double-StrandedAdenosine DeaminaseProtein IsoformsInterferon-Induced Helicase, IFIH1Zbp1 protein, mouseRNA-Binding ProteinsADAR1 protein, mouse

Autor:innen und Institutionen

  • Department of RNA Biology and Neuroscience, Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan.
  • Integrated Frontier Research for Medical Science Division and RNA Frontier Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University, Suita, Osaka 565-0871, Japan.
  • Division of Microbiology and Immunology, Center for Infectious Disease Education and Research (CiDER), Osaka University, Suita, Osaka 565-0871, Japan.

ORCID-Profile: Yukio Kawahara

Förderung

  • Japan Society for the Promotion of Science
  • Ministry of Education, Culture, Sports, Science and Technology
  • Japan Agency for Medical Research and Development
  • Japan Intractable Diseases Research Foundation
  • Astellas Foundation for Research on Metabolic Disorders
  • Uehara Memorial Foundation
  • Waksman Foundation of Japan
  • Senri Life Science Foundation

Zitieren

APA

Nakahama, T., & Kawahara, Y. (2023). The RNA-editing enzyme ADAR1: a regulatory hub that tunes multiple dsRNA-sensing pathways. International Immunology, 35(3), 123-133. https://doi.org/10.1093/intimm/dxac056

Vancouver

Nakahama T, Kawahara Y. The RNA-editing enzyme ADAR1: a regulatory hub that tunes multiple dsRNA-sensing pathways. International Immunology. 2023;35(3):123-133. doi:10.1093/intimm/dxac056

BibTeX
@article{Nakahama2023,
  author = {Nakahama, Taisuke and Kawahara, Yukio},
  title = {The RNA-editing enzyme ADAR1: a regulatory hub that tunes multiple dsRNA-sensing pathways},
  journal = {International Immunology},
  year = {2023},
  volume = {35},
  number = {3},
  pages = {123--133},
  doi = {10.1093/intimm/dxac056}
}
Kostenlos starten →